STXS logo

Stereotaxis (STXS) Company Overview

Profile

Full Name:

Stereotaxis, Inc.

Sector:

Healthcare

Country:

United States

IPO:

August 12, 2004

Indexes:

Not included

Description:

Stereotaxis (STXS) specializes in advanced robotic systems for cardiac procedures. Their technology enhances precision in catheter navigation, improving patient outcomes in heart surgeries. The company focuses on innovation in medical devices, aiming to transform the way doctors perform complex procedures.

Events Calendar

Earnings

Next earnings date:

Mar 4, 2025

Recent quarterly earnings:

Nov 11, 2024

Recent annual earnings:

Mar 4, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Nov 4, 2013

Analyst ratings

Recent major analysts updates

Mar 5, 24 Roth MKM
Buy
Mar 5, 24 Lake Street
Buy
Jan 10, 24 Roth MKM
Buy
Mar 6, 23 Piper Sandler
Overweight
Mar 6, 23 Lake Street
Buy
Mar 6, 23 B. Riley Securities
Buy
Nov 11, 22 Cowen & Co.
Outperform
Sep 2, 22 B. Riley Securities
Buy
Jul 12, 22 Aegis Capital
Buy
Jun 23, 22 B. Riley Securities
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

STXS Stock Gains Following the First Order for its GenesisX
STXS Stock Gains Following the First Order for its GenesisX
STXS Stock Gains Following the First Order for its GenesisX
STXS
zacks.comFebruary 4, 2025

Stereotaxis receives its first order for the next-generation robotic system, GenesisX. The company expects a full commercial launch in the coming months.

Stereotaxis Announces First GenesisX Robotic System Order
Stereotaxis Announces First GenesisX Robotic System Order
Stereotaxis Announces First GenesisX Robotic System Order
STXS
globenewswire.comJanuary 30, 2025

ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has received the first order for its latest generation robotic system, GenesisX™.

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter
STXS
globenewswire.comJanuary 27, 2025

ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it received European CE Mark approval for the MAGiC™ ablation catheter. This approval is a significant milestone for Stereotaxis and for the community of physicians pioneering robotics in electrophysiology. It is reflective of the company's commitment to advancing significant innovations that make robotics increasingly impactful across interventional medicine.

STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
STXS Stock Up Post NMPA Nod for Cardiovascular Care With Magbot
STXS
zacks.comDecember 16, 2024

Stereotaxis' latest regulatory approval in China is likely to offer a minimally-invasive treatment solution for complex arrhythmia patients and improve global cardiovascular care.

Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
Stereotaxis' GenesisX Robotic System to be Showcased for the First Time at RSNA 2024 by Neusoft Medical Systems
STXS
globenewswire.comDecember 2, 2024

ST. LOUIS and SHENYANG, China, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Neusoft Medical Systems Co., Ltd (“Neusoft Medical Systems”) today announced that Stereotaxis' latest GenesisX robotic system is being featured for the first time at Neusoft Medical Systems' booth at the Radiology Society of North America's (RSNA) 2024 Annual Meeting taking place December 1-5 in Chicago, IL.

Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
Stereotaxis To Drive Transformational Growth Via Full Ecosystem Launch In 2025
STXS
seekingalpha.comDecember 2, 2024

MAGiC is set to receive the CE Mark by early 2025. Tenders will be completed by Q2 or Q3 2025; the FDA approval timeline is similar. The APT acquisition allowed Stereotaxis to complete the manufacturing of its robotic mapping and guidecatheter for regulatory submissions in Q1 2025. STXS's holistic ecosystem approach, including interventional devices, GenesisX, and digital surgery advancements, aims to solve long-standing issues with robotic adoption in EP.

STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
STXS Stock Up Following the NMPA Clearance of Its Genesis RMN System
STXS
zacks.comNovember 26, 2024

Stereotaxis, in collaboration with MicroPort EP, announces the receipt of NMPA approval for its Genesis RMN System.

Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
Stereotaxis Genesis Robotic System Achieves Regulatory Approval in China
STXS
globenewswire.comNovember 25, 2024

ST. LOUIS and SHANGHAI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced regulatory approval of the Genesis RMN ® System by China's National Medical Products Administration (NMPA).

Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
Hospital Da Luz is the First in Portugal to Adopt Genesis Robotic System
STXS
globenewswire.comNovember 20, 2024

ST. LOUIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at the Hospital da Luz in Lisbon, Portugal have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System.

Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
Stereotaxis, Inc. (STXS) Q3 2024 Earnings Call Transcript
STXS
seekingalpha.comNovember 11, 2024

Stereotaxis, Inc. (NYSE:STXS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants David Fischel - Chairman and Chief Executive Officer Kimberly Peery - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Josh Jennings - TD Cowen Adam Maeder - Piper Sandler Operator Good afternoon. Thank you for joining us for Stereotaxis Third Quarter 2024 Earnings Conference Call.

FAQ

  • What is the ticker symbol for Stereotaxis?
  • Does Stereotaxis pay dividends?
  • What sector is Stereotaxis in?
  • What industry is Stereotaxis in?
  • What country is Stereotaxis based in?
  • When did Stereotaxis go public?
  • Is Stereotaxis in the S&P 500?
  • Is Stereotaxis in the NASDAQ 100?
  • Is Stereotaxis in the Dow Jones?
  • When was Stereotaxis's last earnings report?
  • When does Stereotaxis report earnings?
  • Should I buy Stereotaxis stock now?

What is the ticker symbol for Stereotaxis?

The ticker symbol for Stereotaxis is NYSE American:STXS

Does Stereotaxis pay dividends?

No, Stereotaxis does not pay dividends

What sector is Stereotaxis in?

Stereotaxis is in the Healthcare sector

What industry is Stereotaxis in?

Stereotaxis is in the Medical Instruments & Supplies industry

What country is Stereotaxis based in?

Stereotaxis is headquartered in United States

When did Stereotaxis go public?

Stereotaxis's initial public offering (IPO) was on August 12, 2004

Is Stereotaxis in the S&P 500?

No, Stereotaxis is not included in the S&P 500 index

Is Stereotaxis in the NASDAQ 100?

No, Stereotaxis is not included in the NASDAQ 100 index

Is Stereotaxis in the Dow Jones?

No, Stereotaxis is not included in the Dow Jones index

When was Stereotaxis's last earnings report?

Stereotaxis's most recent earnings report was on Nov 11, 2024

When does Stereotaxis report earnings?

The next expected earnings date for Stereotaxis is Mar 4, 2025

Should I buy Stereotaxis stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions